Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4B | O94953 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480598 | 1.00 | GCG (0.33) | GCGHDAC4MELKKDM4AKDM4B | |
| SCHEMBL29480597 | 0.94 | HDAC4 (0.34) | HDAC4GRM4 | |
| SCHEMBL22736027 | 0.94 | HDAC4 (0.34) | HDAC4GRM4 | |
| SCHEMBL22735900 | 0.92 | HDAC4 (0.33) | GCGHDAC4KDM4AKDM4BKDM5C | |
| SCHEMBL29480513 | 0.92 | HDAC4 (0.33) | GCGHDAC4KDM4AKDM4BKDM5C | |
| SCHEMBL22716786 | 0.92 | HDAC4 (0.33) | GCGHDAC4GRM4 | |
| SCHEMBL29480492 | 0.92 | HDAC4 (0.33) | GCGHDAC4GRM4 | |
| SCHEMBL22716875 | 0.91 | MELK (0.34) | HDAC4MELKGRM4 | |
| SCHEMBL29480614 | 0.91 | MELK (0.34) | HDAC4MELKGRM4 | |
| SCHEMBL22735904 | 0.89 | KDM4A (0.36) | HDAC4MELKKDM4AKDM4BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020240586-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2020-12-03 | — | — | WO | disclosed |